Vaccine for mycoplasma infection
Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma -mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma -mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma -mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma -mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
1. Mycoplasma -mimic particles, comprising:
liposome particles including at least one mycoplasma -specific lipid antigen, a liposome-constituting lipid component and at least one other antigenic substance on the surfaces of the liposome particles,
wherein the antigenicity of each of the at least one other antigenic substance increases by adjuvant effects of the mycoplasma -specific lipid antigen.
2. The mycoplasma -mimic particles according to claim 1 , wherein the at least one other antigenic substance is a virus-derived antigen peptide.
3. A method of suppressing or treating a disease caused by a mycoplasma infection, comprising:
a process of administering a vaccine for suppressing or treating of a disease caused by a mycoplasma infection at least once to human or an animal that is affected or suspected to be affected with the mycoplasma infection,
wherein the vaccine comprises mycoplasma -mimic particles as an active ingredient and a pharmaceutically acceptable excipient,
wherein the mycoplasma -mimic particles comprise liposome particles including at least one mycoplasma -specific glycolipid antigen as a liposome-constituting lipid component,
wherein the at least one mycoplasma -specific glycolipid antigen is chemically or enzymatically synthesized, and then separated and purified.
4. The method of treating a disease caused by mycoplasma infection according to claim 3 , further comprising:
measuring the amount of a mycoplasma species-specific lipid antigen or the amount of a lipid antigen-specific antibody before and/or after administration of the vaccine, and
determining administration time and dosage amount of the next vaccine based on the measured value.
5. A vaccine for prevention or treatment of a disease caused by a virus infection, comprising: the mycoplasma -mimic particles according to claim 2 containing a virus-derived antigen peptide on the surface of the particles as an active ingredient and a pharmaceutically acceptable excipient.
6. The vaccine according to claim 5 , wherein the virus is influenza virus and the disease is influenza.
7. A method of suppressing or treating a disease caused by a virus infection, comprising:
administering the vaccine for suppression or treatment of a disease caused by a virus infection according to claim 5 to human or an animal that is affected or suspected to be affected with the virus infection disease.
8. The suppression or treatment method according to claim 7 , wherein the virus is influenza virus and the disease is influenza.
9. The suppression or treatment method according to claim 3 , wherein
the disease caused by a mycoplasma infection is pneumonia, asthma, or rheumatic disease.